COGNITIVE IMPAIRMENT IN SCHIZOPHRENIA
暂无分享,去创建一个
[1] H. Kraemer,et al. Evaluation of comparative treatment trials: assessing clinical benefits and risks for patients, rather than statistical effects on measures. , 2010, JAMA.
[2] Richie Poulton,et al. Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. , 2010, The American journal of psychiatry.
[3] Larry J. Seidman,et al. NEUROPSYCHOLOGY OF THE PRODROME TO PSYCHOSIS IN THE NAPLS CONSORTIUM: RELATIONSHIP TO FAMILY HISTORY AND CONVERSION TO PSYCHOSIS , 2008, Schizophrenia Research.
[4] R. Hamer,et al. Feasibility and Pilot Efficacy Results from the Multi-site Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) Study , 2010 .
[5] D. Barch,et al. Anticipating DSM-V: opportunities and challenges for cognition and psychosis. , 2010, Schizophrenia bulletin.
[6] Philip D. Harvey,et al. Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. , 2009, Schizophrenia bulletin.
[7] R. Keefe,et al. Memory-Prediction Errors and Their Consequences in Schizophrenia , 2009, Neuropsychology Review.
[8] R. Keefe,et al. Measuring memory-prediction errors and their consequences in youth at risk for schizophrenia. , 2009, Annals of the Academy of Medicine, Singapore.
[9] J. Lieberman,et al. Relationship of cognition and psychopathology to functional impairment in schizophrenia. , 2008, The American journal of psychiatry.
[10] Michael F. Green,et al. Identifying Cognitive Mechanisms Targeted for Treatment Development in Schizophrenia: An Overview of the First Meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative , 2008, Biological Psychiatry.
[11] Herbert Y Meltzer,et al. Efficacy and Safety of Donepezil in Patients with Schizophrenia or Schizoaffective Disorder: Significant Placebo/Practice Effects in a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial , 2008, Neuropsychopharmacology.
[12] Philip D. Harvey,et al. Functional implications of neuropsychological normality and symptom remission in older outpatients diagnosed with schizophrenia: A cross-sectional study , 2008, Journal of the International Neuropsychological Society.
[13] Philip D. Harvey,et al. Usefulness of the UCSD performance-based skills assessment (UPSA) for predicting residential independence in patients with chronic schizophrenia. , 2008, Journal of psychiatric research.
[14] Michael F. Green,et al. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. , 2008, The American journal of psychiatry.
[15] Michael F. Green,et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. , 2008, The American journal of psychiatry.
[16] Philip D. Harvey,et al. Implementation considerations for multisite clinical trials with cognitive neuroscience tasks. , 2007, Schizophrenia bulletin.
[17] Tyrone D. Cannon,et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. , 2008, Archives of general psychiatry.
[18] E. Twamley,et al. A meta-analysis of cognitive remediation in schizophrenia. , 2007, The American journal of psychiatry.
[19] Michael F. Green,et al. How neurocognition and social cognition influence functional change during community-based psychosocial rehabilitation for individuals with schizophrenia. , 2007, Schizophrenia bulletin.
[20] Philip D. Harvey,et al. Performance-based measures of functional skills: usefulness in clinical treatment studies. , 2007, Schizophrenia bulletin.
[21] C. Carter,et al. Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. , 2007, Schizophrenia bulletin.
[22] W. Fenton,et al. How should DSM-V criteria for schizophrenia include cognitive impairment? , 2007, Schizophrenia bulletin.
[23] Michael F. Green,et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. , 2007, Archives of general psychiatry.
[24] J. Gold,et al. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. , 2007, Archives of general psychiatry.
[25] S. McGurk,et al. Cognitive training for supported employment: 2-3 year outcomes of a randomized controlled trial. , 2007, The American journal of psychiatry.
[26] Philip D. Harvey,et al. Correlations of functional capacity and neuropsychological performance in older patients with schizophrenia: Evidence for specificity of relationships? , 2007, Schizophrenia Research.
[27] Diana O. Perkins,et al. A longitudinal study of neurocognitive function in individuals at-risk for psychosis , 2006, Schizophrenia Research.
[28] J. Sweeney,et al. Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. , 2006, Archives of general psychiatry.
[29] Michael F. Green,et al. Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial , 2006, Neuropsychopharmacology.
[30] J. Lieberman,et al. Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic , 2006 .
[31] Philip D. Harvey,et al. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. , 2005, The American journal of psychiatry.
[32] M. Chee,et al. fMRI study of maintenance and manipulation processes within working memory in first-episode schizophrenia. , 2005, The American journal of psychiatry.
[33] Margaret P. Poe,et al. Defining a cognitive function decrement in schizophrenia , 2005, Biological Psychiatry.
[34] Michael F. Green,et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. , 2005, Schizophrenia bulletin.
[35] W. Gaebel,et al. Facial expression and emotional face recognition in schizophrenia and depression , 2005, European Archives of Psychiatry and Clinical Neuroscience.
[36] C. Pantelis,et al. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. , 2005, The American journal of psychiatry.
[37] Michael F. Green,et al. Identification of separable cognitive factors in schizophrenia , 2004, Schizophrenia Research.
[38] J. Callicott,et al. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. , 2004, The American journal of psychiatry.
[39] Michael F. Green,et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria , 2004, Biological Psychiatry.
[40] R. Gibbs,et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[41] J. Lieberman,et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. , 2004, The American journal of psychiatry.
[42] T. McGlashan,et al. Neuropsychological status of subjects at high risk for a first episode of psychosis , 2004, Schizophrenia Research.
[43] Michael F. Green,et al. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. , 2004, The Journal of clinical psychiatry.
[44] Steven G Potkin,et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia , 2004, Schizophrenia Research.
[45] M. Davidson,et al. Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode , 2003, Schizophrenia Research.
[46] C. Pantelis,et al. Impairment of olfactory identification ability in individuals at ultra-high risk for psychosis who later develop schizophrenia. , 2003, The American journal of psychiatry.
[47] R. Gur,et al. Working memory deficit as a core neuropsychological dysfunction in schizophrenia. , 2003, The American journal of psychiatry.
[48] Christian R. Dolder,et al. Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia , 2003, Schizophrenia Research.
[49] S. McGurk,et al. Cognitive and symptom predictors of work outcomes for clients with schizophrenia in supported employment. , 2003, Psychiatric services.
[50] S. Potkin,et al. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. , 2003, The Journal of clinical psychiatry.
[51] Jane S. Paulsen,et al. The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenia patients , 2003, Biological Psychiatry.
[52] Michael F. Green,et al. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study , 2003, Psychopharmacology.
[53] Steven J Luck,et al. Working memory for visual features and conjunctions in schizophrenia. , 2003, Journal of abnormal psychology.
[54] S. Hyman,et al. What Are the Right Targets for Psychopharmacology? , 2003, Science.
[55] Lisa M LaVange,et al. Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies. , 2003, Schizophrenia bulletin.
[56] S. Hyman,et al. Medicine. What are the right targets for psychopharmacology? , 2003, Science.
[57] T. Stroup,et al. Assessing Clinical and Functional Outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (catie) Schizophrenia Trial Send Reprint Requests to Clinical Outcome Measures: Primary Outcome Clinical and Functional Outcomes Table 1. Catie Schizophrenia Trial Centers' Clinical and Func , 2022 .
[58] R. Rosenheck,et al. Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs. , 2003, Schizophrenia bulletin.
[59] T. Patterson,et al. Generalized cognitive impairments, ability to perform everyday tasks, and level of independence in community living situations of older patients with psychosis. , 2002, The American journal of psychiatry.
[60] M. Munetz. Negative Symptom and Cognitive Deficit Treatment Response in Schizophrenia , 2002 .
[61] J. McEvoy,et al. Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources , 2002, Schizophrenia Research.
[62] A. Malla,et al. Symptoms, cognition, treatment adherence and functional outcome in first-episode psychosis , 2002, Psychological Medicine.
[63] L. Dixon,et al. Cognitive correlates of job tenure among patients with severe mental illness. , 2002, The American journal of psychiatry.
[64] Beng-Choon Ho,et al. Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. , 2002, The American journal of psychiatry.
[65] L. Friedman. Psychoanalysis: Practice and Technique , 2002, Journal of the American Psychoanalytic Association.
[66] Brian Sheitman,et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. , 2002, The American journal of psychiatry.
[67] A. Ertugrul,et al. The influence of neurocognitive deficits and symptoms on disability in schizophrenia , 2002, Acta psychiatrica Scandinavica.
[68] Philip D. Harvey,et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia , 2002, Biological Psychiatry.
[69] T. Patterson,et al. Medication Management Ability Assessment: Results From a Performance-Based Measure in Older Outpatients With Schizophrenia , 2002, Journal of clinical psychopharmacology.
[70] T. Burke,et al. Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis , 2001, European Psychiatry.
[71] P. Pattison,et al. Facial affect and affective prosody recognition in first-episode schizophrenia , 2001, Schizophrenia Research.
[72] Philip D. Harvey,et al. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. , 2001, The American journal of psychiatry.
[73] M. Green,et al. Neuropsychological functioning as a moderator of the relationship between psychosocial functioning and the subjective experience of self and life in schizophrenia. , 2001, Schizophrenia bulletin.
[74] T L Patterson,et al. UCSD Performance-Based Skills Assessment , 2016 .
[75] M. Bell,et al. Work rehabilitation in schizophrenia: does cognitive impairment limit improvement? , 2001, Schizophrenia bulletin.
[76] D. Ziedonis,et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. , 2000, The American journal of psychiatry.
[77] R. Coppola,et al. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. , 2000, Cerebral cortex.
[78] Herbert Y Meltzer,et al. The role of cognition in vocational functioning in schizophrenia , 2000, Schizophrenia Research.
[79] Alexander L. Miller,et al. Do specific neurocognitive deficits predict specific domains of community function in schizophrenia? , 2000, The Journal of nervous and mental disease.
[80] Jean Addington,et al. Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study , 2000, Schizophrenia Research.
[81] B H Mulsant,et al. Pharmacologic profile of perphenazine's metabolites. , 2000, Journal of clinical psychopharmacology.
[82] A Labelle,et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. , 2000, Archives of general psychiatry.
[83] The paradox of normal neuropsychological function in schizophrenia. , 2000, Journal of abnormal psychology.
[84] D. Braff,et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? , 2000, Schizophrenia bulletin.
[85] R. Kahn,et al. Memory impairment in schizophrenia: a meta-analysis. , 1999, The American journal of psychiatry.
[86] A Reichenberg,et al. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. , 1999, The American journal of psychiatry.
[87] Jane S. Paulsen,et al. Generalized cognitive deficits in schizophrenia: a study of first-episode patients. , 1999, Archives of general psychiatry.
[88] Norman Ringel,et al. Social functioning and neurocognitive deficits in outpatients with schizophrenia: a 2-year follow-up 1 This work was presented in part at the Winter Workshop on Schizophrenia, Davos, Switzerland, 7–13 February 1998. 1 , 1999, Schizophrenia Research.
[89] Kathleen S. Jarboe,et al. The Relationship Between Medication Noncompliance and Cognitive Function in Patients With Schizophrenia , 1999 .
[90] R. Coppola,et al. Physiological characteristics of capacity constraints in working memory as revealed by functional MRI. , 1999, Cerebral cortex.
[91] B. Everitt,et al. The effects of neurocognitive remediation on executive processing in patients with schizophrenia. , 1999, Schizophrenia bulletin.
[92] M. Birchwood,et al. ‘Theory of mind’ skills during an acute episode of psychosis and following recovery , 1998, Psychological Medicine.
[93] J. Addington,et al. Facial affect recognition and information processing in schizophrenia and bipolar disorder , 1998, Schizophrenia Research.
[94] Philip D. Harvey,et al. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. , 1998, The American journal of psychiatry.
[95] R. Heinrichs,et al. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. , 1998, Neuropsychology.
[96] M. Bell,et al. Wisconsin Card Sorting Test dimensions in schizophrenia: factorial, predictive, and divergent validity. , 1997, Journal of clinical and experimental neuropsychology.
[97] A. David,et al. IQ and risk for schizophrenia: a population-based cohort study , 1997, Psychological Medicine.
[98] Philip D. Harvey,et al. Cognitive Impairment in Schizophrenia and Implications of Atypical Neuroleptic Treatment , 1997, CNS Spectrums.
[99] Jane S. Paulsen,et al. Is it possible to be schizophrenic yet neuropsychologically normal? , 1997, Neuropsychology.
[100] J. Nadel,et al. Attribution of mental States to others by schizophrenic patients. , 1997, Cognitive Neuropsychiatry.
[101] J. Long,et al. The impact of service characteristics on functional outcomes from community support programs for persons with schizophrenia: a growth curve analysis. , 1997, Journal of Consulting and Clinical Psychology.
[102] W S Fenton,et al. Determinants of medication compliance in schizophrenia: empirical and clinical findings. , 1997, Schizophrenia bulletin.
[103] C. Carter,et al. Spatial working memory deficits and their relationship to negative symptoms in unmedicated schizophrenia patients , 1996, Biological Psychiatry.
[104] D. Penn,et al. The relationship of social cognition to ward behavior in chronic schizophrenia , 1996, Schizophrenia Research.
[105] Michael F. Green,et al. What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.
[106] S. Bressi,et al. Deficit of central executive component of working memory in schizophrenia , 1996 .
[107] A. Yung,et al. The prodromal phase of first-episode psychosis: past and current conceptualizations. , 1996, Schizophrenia bulletin.
[108] S. Sevy,et al. The cost of cognitive impairment in schizophrenia , 1995, Schizophrenia Research.
[109] C. Frith,et al. Schizophrenia, symptomatology and social inference: Investigating “theory of mind” in people with schizophrenia , 1995, Schizophrenia Research.
[110] M. Bell,et al. Work Rehabilitation and Improvements in Insight in Schizophrenia , 1995, The Journal of nervous and mental disease.
[111] Philip D. Harvey,et al. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. , 1995, The American journal of psychiatry.
[112] R. Keefe. The contribution of neuropsychology to psychiatry. , 1995, The American journal of psychiatry.
[113] R. Buchanan,et al. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance , 1994, Biological Psychiatry.
[114] M Marmot,et al. Child developmental risk factors for adult schizophrenia in the British 1946 birth cohort , 1994, The Lancet.
[115] M. Tohen,et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. , 1994 .
[116] P. Goldman-Rakic. Working memory dysfunction in schizophrenia. , 1994, The Journal of neuropsychiatry and clinical neurosciences.
[117] B. Cornblatt,et al. Impaired attention, genetics, and the pathophysiology of schizophrenia. , 1994, Schizophrenia bulletin.
[118] M. Strauss,et al. Relations of symptoms to cognitive deficits in schizophrenia. , 1993, Schizophrenia bulletin.
[119] A. Baddeley,et al. Memory impairment in schizophrenia: its extent, affiliations and neuropsychological character , 1992, Psychological Medicine.
[120] Jean Addington,et al. Cognitive functioning and positive and negative symptoms in schizophrenia , 1991, Schizophrenia Research.
[121] R. Gur,et al. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. , 1991, Archives of general psychiatry.
[122] K. Mueser,et al. Prediction of social skill acquisition in schizophrenic and major affective disorder patients from memory and symptomatology , 1991, Psychiatry Research.
[123] S. Marder,et al. Neuroleptic plasma levels. , 1991, Schizophrenia bulletin.
[124] R. Liberman,et al. From noncompliance to collaboration in the treatment of schizophrenia. , 1990, Hospital & community psychiatry.
[125] J. Ragland,et al. Neuropsychological assessment of monozygotic twins discordant for schizophrenia. , 1990, Archives of general psychiatry.
[126] E. Walker,et al. The positive/negative symptom distinction in schizophrenia validity and etiological relevance , 1988, Schizophrenia Research.
[127] K. Mueser,et al. Deficits in facial-affect recognition and schizophrenia. , 1988, Schizophrenia bulletin.
[128] T. Goldberg,et al. Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test. , 1987, Archives of general psychiatry.
[129] P S Goldman-Rakic,et al. Circuitry of the frontal association cortex and its relevance to dementia. , 1987, Archives of gerontology and geriatrics.
[130] D. Weinberger. Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.
[131] R. Bilder,et al. Symptomatic and neuropsychological components of defect states. , 1985, Schizophrenia bulletin.
[132] R. Heaton,et al. Use of Neuropsychological tests to predict adult patients' everyday functioning. , 1981, Journal of consulting and clinical psychology.